Combined Prognostic Value of Preprocedural Protein–Energy Wasting and Inflammation Status for Amputation and/or Mortality after Lower-Extremity Revascularization in Hemodialysis Patients with Peripheral Arterial Disease

Author:

Kumada Yoshitaka1,Kawai Norikazu1,Ishida Narihiro1,Nakamura Yasuhito1,Takahashi Hiroshi2,Ohshima Satoru3,Ito Ryuta3,Izawa Hideo2ORCID,Murohara Toyoaki4,Ishii Hideki5ORCID

Affiliation:

1. Department of Cardiovascular Surgery, Matsunami General Hospital, Kasamatsu 501-6062, Japan

2. Department of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan

3. Department of Cardiology, Nagoya Kyoritsu Hospital, Nagoya 454-0933, Japan

4. Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

5. Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan

Abstract

Protein–energy wasting is associated with inflammation and advanced atherosclerosis in hemodialysis patients. We enrolled 800 patients who had undergone successful lower-extremity revascularization, and we investigated the association among the Geriatric Nutritional Risk Index (GNRI) as a surrogate marker of protein–energy wasting, C-reactive protein (CRP), and their joint roles in predicting amputation and mortality. They were divided into lower, middle, and upper tertiles (T1, T2, and T3) according to GNRI and CRP levels, respectively. Regarding the results, the amputation-free survival rates over 8 years were 47.0%, 56.9%, and 69.5% in T1, T2, and T3 of the GNRI and 65.8%, 58.7%, and 33.2% for T1, T2, and T3 of CRP, respectively (p < 0.0001 for both). A reduced GNRI [adjusted hazard ratio (aHR) 1.78, 95% confidence interval (CI) 1.24–2.59, p = 0.0016 for T1 vs. T3] and elevated CRP (aHR 1.86, 95% CI 1.30–2.70, p = 0.0007 for T3 vs. T1) independently predicted amputation and/or mortality. When the two variables were combined, the risk was 3.77-fold higher (95% CI 1.97–7.69, p < 0.0001) in patients who occupied both T1 of the GNRI and T3 of CRP than in those who occupied both T3 of the GNRI and T1 of CRP. In conclusion, patients with preprocedurally decreased GNRI and elevated CRP levels frequently experienced amputation and mortality, and a combination of these two variables could more accurately stratify the risk.

Funder

Bayer

Sumitomo Pharma

PDR Pharma

Biotronik Japan

Abbott Japan

Boston Scientific Japan

Japan Lifeline

Medtronic Japan

Otsuka

Novartis

Eli Lilly Japan

Nippon Boehringer Ingelheim

Daiichi Sankyo

Kowa Co., Ltd.

MSD K.K.

Mitsubishi Tanabe Pharma Co.

Pfizer Japan Inc.

Sanofi-aventis K.K.

Takeda Pharmaceutical Co., Ltd.

Department of Cardiology, Nagoya University Graduate School of Medicine

Daiichi Sankyo Co., Ltd.

Teijin Pharma Ltd.

Astrazeneca Inc.

Bristol-Myers Squibb Inc.

Chugai Pharmaceutical Co., Ltd.

Publisher

MDPI AG

Subject

General Medicine

Reference39 articles.

1. GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709–733.

2. GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736–1788.

3. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016—40 for 195 countries and territories;Foreman;Lancet,2018

4. Prognostic Value of Chronic Kidney Disease Measures in Patients with Cardiac Disease;Mok;Circ. J.,2017

5. Novel “Predictor Patch” Method for Adding Predictors Using Estimates from Outside Datasets—A Proof-of-Concept Study Adding Kidney Measures to Cardiovascular Mortality Prediction;Matsushita;Circ. J.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3